ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2353

Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies

Philip Mease1, Alice Gottlieb2, Iain McInnes3, Natalie J. Shiff4, Toby Thomas5, Emmanouil Rampakakis6, Francois Nantel7, Frederic Lavie8 and Proton Rahman9, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, 3University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 4Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, 5Janssen Pharmaceuticals, Horsham, PA, 6McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 7Nantel MedSci Consult, Montreal, QC, Canada, 8Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 9Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada

Meeting: ACR Convergence 2024

Keywords: Biologicals, Psoriatic arthritis, radiography, Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint and skin symptoms in active PsA patients (pts). In D2, GUS-treated pts had lower rates of radiographic progression (RP) vs placebo (PBO) at W24, with durable suppression of RP through 2 years.1,2 Assessing the impact of GUS on joint disease activity (DA)/progression using an instrument suitable for routine care may facilitate disease monitoring in this setting. The clinical DA Index for PsA (cDAPSA), a version of DAPSA omitting CRP, performs similarly to DAPSA.3 These post hoc analyses describe the transition between cDAPSA DA states through W52 in GUS- vs PBO-treated PsA pts (pooled D1+D2) and evaluate the association between earlier clinical improvement in joint DA and long-term RP through 2 years in D2.

Methods: D1 (31% TNF inhibitor [TNFi]-experienced) & D2 (biologic-naïve) enrolled adults with active PsA despite conventional synthetic csDMARDs. Pts were randomized 1:1:1 to GUS 100 mg Q4W; GUS 100 mg at W0, W4, then Q8W; or PBO→GUS 100 mg Q4W at W24. Pts with moderate ( >13 to ≤27) or high ( >27) levels of joint DA (ModDA/HDA; cDAPSA >13) at baseline (BL) were included. cDAPSA low DA/remission (LDA/REM; ≤13) rates through W52 were determined using nonresponder imputation for missing data; rates through W24 were compared between GUS vs PBO with logistic regression adjusting for prior TNFi and BL csDMARD use and cDAPSA. Among GUS-randomized pts (RP evaluated) in D2, a predictive model (mixed linear) assessed associations between W8 improvement in DA (shift from cDAPSA ModDA/HDA→LDA/REM) and changes in total PsA-modified van der Heijde-Sharp [vdH-S] score through W100, after adjusting for known BL determinants of RP (vdH-S score, age, gender, CRP).

Results: Of 1120 D1&2 pts, 947 (84.6%: cDAPSA HAD) and 166 (14.8%: ModDA) were evaluated. W8 cDAPSA LDA/REM rates were significantly higher in GUS Q4W/Q8W pts vs PBO (18.8%/17%; vs 7.3%; p≤0.0001); corresponding W8 odds ratios (OR) vs PBO were enhanced by W24 (ORQ4W=3.0→3.3; ORQ8W=2.6→3.2). Response rates increased through W52 of GUS Q4W and Q8W (Fig 1). Among GUS-randomized D2 pts, achievement of cDAPSA LDA/REM at W8 associated with significantly lower rates of RP through W100. The effect of W8 cDAPSA LDA/REM on future RP strengthened over time among achievers vs non-achievers (least square means difference at W52= ‑1.03 [p=0.03] and W100= ‑1.87 [p=0.01]; Fig 2).

Conclusion: Among PsA pts with ModDA/HDA, GUS was associated with significantly greater rates of cDAPSA LDA/REM achievement vs PBO at W8 (after 2 doses). Response rates increased over time, with nearly 40% and >50% of GUS-randomized pts achieving cDAPSA LDA/REM at Weeks 24 and 52, respectively. Earlier improvements in joint DA (W8 cDAPSA LDA/REM) among biologic-naïve GUS-treated pts associated with significantly lower RP rates through 2 years. Results highlight the potential utility of cDAPSA in routine care to monitor short-and long-term improvements in joint DA among GUS-treated PsA pts.
 
1.     Mease P. Lancet 2020;395:1126
2.     McInnes I. Arthritis Rheumatol 2022;74:475
3.     Schoels M. Ann Rheum Dis 2016;75:811

Supporting image 1

Supporting image 2


Disclosures: P. Mease: AbbVie, 2, 5, Aclaris Therapeutics, 2, 5, Aclyrin, 2, 5, Amgen, 2, 5, Boehringer Ingelheim, 2, 5, Bristol Myers Squibb, 2, 5, CorEvitas, 2, 5, Galápagos, 2, 5, Gilead, 2, 5, Inmagene, 2, 5, Janssen, 2, 5, Lilly, 2, 5, MoonLake Immunotherapeutics, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sun Pharma, 2, 5, UCB, 2, 5; A. Gottlieb: Amgen, 1, 2, AnaptypsBio, 1, 2, Avotres Therapeutics, 1, 2, Boehringer Ingelheim, 1, 2, Bristol Myers Squibb, 1, 2, 5, Dice Therapeutics, 1, 2, Eli Lilly, 1, 2, Highlights Therapeutics, 1, 2, 5, Janssen, 1, 2, 5, Novartis, 1, 2, Sanofi, 1, 2, Teva, 1, 2, UCB, 1, 2, 5, Xbiotech, 1, 2; I. McInnes: AbbVie, 2, 5, 6, Amgen, 2, Bristol Myers Squibb, 2, 5, Cabaletta, 2, Celgene, 2, Compugen, 2, Dextera, 2, Eli Lilly, 2, 5, Janssen, 2, 5, Moonlake, 2, Novartis, 2, 5, Pfizer, 2, UCB, 2, 5, 6; N. Shiff: AbbVie, 11, Childhood Arthritis and Rheumatology Research Alliance, 12, received salary support, within the past 3 years, Gilead, 11, Iovance, 11, Janssen Scientific Affairs, LLC, 3, Jazz, 11, Johnson & Johnson, 11, Novavax, 11, Novo-Nordisk, 11, Pfizer, 11, Viatris, 11; T. Thomas: Janssen, 3, Johnson & Johnson, 11; E. Rampakakis: Janssen, 2, JSS Medical Research, 3; F. Nantel: Janssen, 2, Johnson & Johnson, 11; F. Lavie: Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, 3, Johnson & Johnson, 11; P. Rahman: AbbVie, 2, Amgen, 2, Bristol Myers Squibb, 2, Celgene, 2, Eli Lilly, 2, Janssen, 2, 5, 12, Meeting attendance/travel support, Novartis, 2, 5, Pfizer, 2, UCB, 2.

To cite this abstract in AMA style:

Mease P, Gottlieb A, McInnes I, Shiff N, Thomas T, Rampakakis E, Nantel F, Lavie F, Rahman P. Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/effects-of-guselkumab-on-cdapsa-disease-activity-state-and-its-association-with-long-term-radiographic-progression-in-a-cohort-of-patients-with-moderately-highly-active-psoriatic-arthritis-post-hoc-a/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-guselkumab-on-cdapsa-disease-activity-state-and-its-association-with-long-term-radiographic-progression-in-a-cohort-of-patients-with-moderately-highly-active-psoriatic-arthritis-post-hoc-a/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology